Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that if BCL2 deregulation does indeed occur in MM, a mechanism other than translocation must be involved in most cases.
|
1415486 |
1992 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is at present unclear whether the high expression of bcl-2 in human myeloma is the result of a deregulated expression associated with the malignant phenotype or a mere reflection of the bcl-2 expression typical of normal plasma cells.
|
1730093 |
1992 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma (MM) is a slow-growing malignancy whose plasma cells express the BCL-2 antiapoptosis gene.
|
7743552 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since both IL-6 and bcl-2 protein have been shown to prevent programmed cell death, this may be the unifying event in MM.
|
8467229 |
1993 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To ascertain if multiple myeloma cells surviving exposure to chemotherapy alter their BCL-2 expression, we treated the myeloma cell lines 8226, IM-9, and U266 as well as a primary myeloma cell culture with various injurious agents.
|
8781438 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied eight myeloma cell lines for the presence of Bcl-2, which inhibits apoptosis, of Bax, which counteracts Bcl-2, of Bcl-x(L) and Bcl-x(S), which act in an anti- and pro-apoptotic fashion, respectively, and of Apo-1/Fas, which induces programmed cell death, when activated by the Apo-1/Fas ligand or the relevant monoclonal antibody (mab).
|
9163609 |
1997 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forced expression of bcl-2 in 8226 and ARP-1 multiple myeloma (MM) cell lines expressing relatively low levels of bcl-2, resulted in 1-2 log increase in resistance to dexamethasone (DEX)-induced apoptosis.
|
9454907 |
1998 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We tested the role of bcl-2 by transfecting 2 low bcl-2-expressing myeloma cell lines, ARP-1 and 8226, with a bcl-2 expression vector and compared the effects of DEX and MEL on apoptosis, cell cycle distribution and the levels of proapoptotic (bax) and antiapoptotic (bcl-2, bclx) proteins.
|
9664139 |
1998 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We studied the cytotoxic effect of TAX and GEM on MM cells expressing varying levels of the antiapoptotic protein bcl-2, which is overexpressed in the majority of myeloma cell from MM patients.
|
9735415 |
1998 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the protective effects of bcl-2 in MM cells act upstream in the NF-kappaB activation-signaling pathway and the potential use of NF-kappaB as a biomarker in progressive MM.
|
10216101 |
1999 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we provide first time evidence that similar to Fas, TRAIL-induced apoptosis is not blocked by bcl-2 in MM cell lines.
|
10557057 |
1999 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 mediated suppression of apoptosis in myeloma NS0 cultures.
|
10812183 |
2000 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD34(+) cells were resistant to Ad-p53-mediated apoptosis, and CFU-GM and BFU-E colony formation was not affected by treatment with Ad-p53.Ad-p53 is a potent inducer of apoptosis in MM cell lines and in freshly isolated myeloma cells expressing low levels of bcl-2.
|
11146157 |
2000 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.
|
11175262 |
2000 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Replication deficient Ad-p53 and human recombinant Apo2L/TRAIL were used.Myeloma cells with mutated/w.t. p53 and varying expression of bcl-2 were used to test the effect of Ad-p53, Apo2L/TRAIL, or both, on apoptosis, measured by annexin V.
|
11495702 |
2001 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To conclude, we suggest that the expression pattern of the Bcl-2 family of proteins separates the malignant phenotype of MM from normal plasma cells, and that the protecting effect of IL-6 may be conducted via an altered balance between these proteins.
|
12366710 |
2002 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
CTD_human |
MM cells express multiple Bcl-2 family members, including Bcl-2, Bcl-XL, and Mcl-1, which are thought to play a key role in the survival and drug resistance of myeloma.
|
12429644 |
2002 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our data demonstrates that loss of p53 function leads to myeloma cell progression and resistant phenotype through bcl-2-related mechanisms.
|
12479855 |
2003 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, high Bcl-2-expressing myeloma cells were practically resistant to Bcl-2-ASO.
|
12521996 |
2003 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
G3139 can consistently enter myeloma cells, downregulate the expression of Bcl-2, and enhance the efficacy of myeloma therapy.
|
12529680 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The study aim was to investigate Stat 3 activation in a series of multiple myeloma (MM) cases and its effect on downstream targets such as the anti-apoptotic proteins Bcl-xL, Mcl-1, and Bcl-2, and the cell-cycle protein cyclin D1.Forty-eight cases of MM were analyzed.
|
12707028 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2 antisense therapy with G3139 (oblimersen sodium; Genasense, Genta Inc, Berkeley Heights, NJ) is in clinical trials for a number of malignancies, including an ongoing trial in myeloma.
|
12720156 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accelerated plasmacytomagenesis in strain C.BCL2 may be useful for designing and testing BCL2 inhibition strategies in human plasma cell tumors overexpressing BCL2, such as Waldenström's macroglobulinemia and multiple myeloma.
|
14695177 |
2003 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conversely, suppression of Bcl-2 enhanced the chemosensitivity of myeloma cells in vitro.
|
15085157 |
2004 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |